Clinical trial Recruiting at 1 site Observational Ages 0 to 99

Natural history assessment of Baker Gordon Syndrome

Official title: A Prospective, Longitudinal and Observational Natural History Study for Children and Adults With Baker Gordon Syndrome - Genetic Autism Alliance

Run by University of Missouri-Columbia · NCT06399952 · Data updated 2026-11-12

This study is trying to learn more about how Baker Gordon Syndrome affects people over time by tracking their symptoms and collecting important health information to help with future treatments.

More Rare Diseases trials

Quick facts

Study typeObservational
Ages0 Years to 99 Years
SexAll
Enrollment50 (estimated)
SponsorUniversity of Missouri-Columbia
Academic / other
Locations1 site (Columbia, Missouri)
StatusRecruiting
StartedApril 30, 2024
Main results expectedMay 5, 2027
Study endsMay 5, 2027
Registry record updatedJune 3, 2026
Trial IDNCT06399952 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals of any age with a genetically confirmed diagnosis of Baker Gordon Syndrome.

Probably not a fit

Patients with unrelated neurodevelopmental conditions or co-morbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to conduct a longitudinal assessment of the clinical progression of individuals with Baker Gordon Syndrome, also known as Synaptotagmin1-Associated Neurodevelopmental Disorder. It will gather baseline measurements and develop outcome measures and diagnostic tools to enhance understanding of the disorder and prepare for future clinical trials. Participants will undergo various assessments, including brain imaging, whole genome sequencing, and the collection of sleep and seizure diaries, while also providing skin samples for stem cell development to study the impact of genetic mutations. The study will focus on identifying factors that correlate with disease development and outcomes.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with Baker Gordon Syndrome.

How similar studies have gone: While this study focuses on a rare condition, similar natural history studies have shown promise in understanding other neurodevelopmental disorders.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Genetically confirmed diagnosis of Baker Gordon syndrome.
* 0-99 years
* Ability to send medical records and diagnostic test results.
* Ability to complete tests and questionnaires.

Exclusion Criteria:

• The presence of another condition or co-morbidity unrelated to Baker Gordon syndrome, that affects neurodevelopment.

In this study, the primary caregivers/LAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.

Caregivers/LAR will have to meet the following inclusion criteria:

* \>18 years.
* Legal caregiver of the patient diagnosed with a Baker Gordon Syndrome.
* Willingness to follow study procedures, as assessed by the research team.
* Willingness to sign the consent form.
* Ability to understand all the information regarding the study, as assessed by the research team.

Caregivers/LAR Exclusion Criteria:

• Less than 18 years old.

Where it's running

  • University of Missouri Columbia
    Columbia, Missouri, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.